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Abstract 
Here we report the first major example of anionic amphibian host defence peptides 
(HDPs) with anticancer activity. Maximin H5 is a C-terminally amidated, anionic host defence 
peptide (MH5N) from toads of the Bombina genus, which was shown to possess activity 
against the glioma cell line, T98G (EC50 = 125 μM). The peptide adopted high levels of α-
helical structure (57.3%) in the presence of model cancer membranes (DMPC:DMPS in a 
molar ratio of 10:1). MH5N also showed a strong ability to penetrate these model membranes 
(Π = 10.5 mN m-1), which correlated with levels of DMPS (R2 > 0.98). Taken with the high 
ability of the peptide to lyse these membranes (65.7%), it is proposed that maximin H5 kills 
cancer cells via membranolytic mechanisms that are promoted by anionic lipid. It was also 
found that C-terminally deaminated maximin H5 (MH5C) exhibited lower levels of α-helical 
structure in the presence of cancer membrane mimics (44.8%) along with a reduced ability to 
penetrate these membranes (Π = 8.1 mN m-1) and induce their lysis (56.6%). These data 
suggested that the two terminal amide groups of native maximin H5 are required for its optimal 
membranolytic and anticancer activity.  
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Highlights 
• Maximin H5 (MH5N) is an anionic, α-helical host defence peptide from amphibians. 
• MH5N kills cancer cells via membranolytic mechanisms promoted by anionic lipid. 
• C-terminal deamidation of MH5N reduces its α-helicity and membranolytic activity. 
Key words  
anticancer activity, α-helical peptide, host defence peptides, lipid monolayers, maximin H5, 
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1.1 Introduction 
Globally, cancer is a leading cause of death that is expected to grow in the coming years 
[1,2] and a host of strategies have been adopted to generate novel anticancer compounds [3,4], 
ranging from the design of nanoparticle drugs [5] to the development of naturally occurring 
plant molecules [6]. Another promising strategy for the development of novel anticancer 
compounds is centred on host defence peptides (HDPs), which are highly effective antibiotics 
of the innate immune system [7]. These peptides have been under investigation as 
therapeutically relevant antimicrobial agents for a number of years but it has become 
increasingly clear that many HDPs also exhibit potent anticancer activity [8–10]. This activity 
generally involves membrane interaction and employs relatively non-specific modes of action 
at multiple sites, which has led to the view that cancer cells have a low likelihood of developing 
resistance to HDPs, potentially giving these peptides a major advantage over many established 
anticancer compounds [7]. Indeed, the rapidly increasing interest in the potential of HDPs to 
act as medically relevant agents in the treatment of cancer is reflected by the fact that a database 
dedicated solely to the anticancer activity of these peptides has recently been launched, namely 
CancerPPD [11]. A number of HDPs have also entered clinical trials as potential anticancer 
agents [12], such as bovine lactoferrin, which was patented in this capacity [13] and was shown 
to reduce the risk of colon carcinogenesis in humans [14]. More recent examples include human 
LL-37 and a synthetic homologue of HDPs, LTX-315, which are both currently awaiting phase 
I / II clinical trials for the treatment of a variety of human cancers, including melanoma and 
lymphoma [15,16]. 
Each of the peptides described above as in clinical trials is cationic, as is the vast 
majority of HDPs that has been reported to exhibit activity against cancer cells [7–9,12]. 
However, an increasing number of anionic HDPs are being reported [17,18] and only a few of 
these peptides have been tested for anticancer activity, mainly those from plants [19,20], such 
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as Cn-AMP2 [21] and kalata B2 [22]. Accordingly, here we have investigated the anticancer 
potential of maximin H5, which is one of a number of anionic HDPs isolated from the skin 
secretions and brains of toads from the Bombina genus [23,24]. The peptide was found to have 
activity against the T98G glioma cell line via membranolytic mechanisms that were promoted 
by anionic lipid in the membranes of these cells and required the two terminal amide groups of 
the peptide for optimal anticancer activity. This would appear to be the first major report of 
anionic amphibian HDPs with anticancer activity. 
  
1.2 Materials and Methods  
 
1.2.1 Reagents 
A synthetic homologue of maximin H5, MH5N (ILGPVLGLVSDTLDDVLGIL-
CONH2), and its C-terminally deamidated isoform, MH5C (ILGPVLGLVSDTLDDVLGIL-
COOH), were manufactured by Pepceuticals (Leicestershire, UK) by solid state synthesis and 
purified by HPLC to purity greater than 95%.  The phospholipids: dimyristoyl 
phosphatidylserine (DMPS) and dimyristoyl phosphatidylcholine (DMPC) were supplied by 
Avanti Polar Lipids (Alabaster, Alabama) and were used without further purification.  All other 
reagents were supplied by SIGMA (UK) and VWR (UK) unless otherwise stated.  
 
1.2.2 The ability of maximin H5 isoforms to kill cancer cells  
The non-cancerous human foetal glial cell line, SVGp12, and the human glioblastoma 
cell line, T98G, were obtained from the European collection of cell cultures 
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(http://www.ecacc.org.uk). These cells were grown and then maintained in Minimum 
Essential Medium Eagle supplemented with 2.5% (v/v) foetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate and 1% (v/v) non-essential amino acids (Lonza, UK). Each 
of these cell lines was maintained in a 37 ºC humidified incubator supplied with 5% CO2, all 
as previously described [25].   To investigate the anticancer potential of maximin H5 isoforms, 
cell cultures were trypsinised and seeded in 96-well microtitre plates (Sarstedt, UK) such that 
wells contained a cell density of either 4500 SVGp12 cells / 200 µl or 4000 T98G cells / 200 
µl. The following day when the cells were circa 70% confluent, MH5N and MH5C (final 
concentration varying between 10 µM and 200 µM) were added to wells and the plates left to 
incubate for 72 hours, all as previously described [25].   After this period of incubation, the 
viability of these peptide-treated cells was determined using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega, UK; MTS assay [26]) according to manufacturer’s 
instructions. Essentially, 20 µl of pre-warmed MTS reagent was added to wells under 
investigation and the plates incubated at 37 oC in a humidified incubator supplied with 5% CO2 
for 60 min. At the end of this time, the absorbance of each well was recorded at 490 nm using 
a Tecan GENios Pro® microplate reader and used to determine % cell viability. As controls, 
these experiments were repeated in the absence of the peptide and, in all cases, experiments 
were performed in quadruplicate. Non-linear regression analysis was used to yield the 
concentration of peptides that inhibited 50% of cancer cell growth (IC50) when compared to 
untreated controls. 
 
1.2.3 Secondary structural analysis of maximin H5 isoforms using circular dichroism 
Secondary structure analysis was performed using a J-815 spectropolarimeter (Jasco, UK) at 
20 °C as previously described [27]. Samples were prepared by dissolving MH5N and MH5C 
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in phosphate buffered saline (PBS) and 2, 2, 2-trifluoroethanol / phosphate buffered saline 
(TFE / PBS; 50% v/v) to give a final peptide concentration of 60 μM in each case. CD structural 
analysis was also performed with MH5N and MH5C in the presence of lipid.  DMPC (19 mg 
ml−1), DMPS (19 mg ml−1) and DMPC:DMPS (molar ratio 10:1) (19 mg ml−1) were dissolved 
in chloroform and dried under N2 gas before being vacuum-dried. The resulting lipid film was 
rehydrated using 1 × PBS (pH 7.5) for an hour, or until the solution was no longer turbid, and 
then freeze-thawed 4 times, followed by extrusion 11 times with a 0.1 μm polycarbonate filter 
using an Avanti Polar Lipids mini-extruder apparatus. Peptide / lipid samples were prepared 
by adding stock peptide solution to a measured volume of lipid suspension to obtain the desired 
peptide:lipid molar ratio (1:100) before being mixed thoroughly. Far UV (180 to 260nm) CD 
spectra were recorded using 0.5 nm intervals, a band width of 1 nm, a scan speed 100 nm min−1 
and a 10 mm path-length cell. Four scans per sample were performed and averaged.  For 
secondary structure estimation, CD spectra was deconvoluted using CDSSTR algorithm 
(protein reference set 3) on the DichroWeb server [28–30].   
 
1.2.4 Interaction of maximin H5 isoforms with lipid monolayers 
Lipid monolayers were formed by dropping chloroformic solutions of either DMPC, DMPS or 
DMPC:DMPS (molar ratio 10:1) onto a Tris buffer subphase (10 mM; pH 7.5) contained in an 
80 ml  601M Langmuir Teflon trough (Biolin Scientific/KSV NIMA, UK).  Surface pressure 
(Π) was measured using a Wilhelmy wire attached to a microbalance.  After spreading, the 
solvent was allowed to evaporate off the subphase surface over 30 minutes, the barriers were 
closed at a rate of 5 cm2 min-1 until a starting pressure of Π = 30 mN m-1 was achieved, which 
is  equivalent to that of the outer leaflet of a cell membrane [31].  Monolayers were allowed to 
equilibrate for a further 30 mins before MH5N and MH5C were injected into the subphase 
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using an L-shaped Hamilton syringe without disruption of the monolayer.  These experiments 
were repeated using monolayers formed from DMPC:DMPS at ratios of 100:1, 50:1, 20:1 and 
10:1  
1.2.5 Interaction of maximin H5 isoforms with dye-filled lipid vesicles  
Either DMPC, DMPS or DMPC:DMPS (molar ratio 10:1) (7.5 mg) were dissolved in 
chloroform and dried under N2 gas before being vacuum-dried. The resulting lipid film was 
then hydrated with 1 ml of HEPES (5.0 mM; pH 7.5) containing calcein (70 mM).  The 
suspension was vortexed for 5 minutes and then sonicated for 30 mins after which, the solution 
underwent 3 cycles of freeze-thawing.  Liposomes were extruded 11 times through a 0.1 µm 
polycarbonate filter using an Avanti polar lipids min-extruder apparatus.  Calcein entrapped 
vesicles were separated from free calcein by gel filtration using a Sephadex G75 column 
(SIGMA) which was rehydrated overnight in HEPES (20 mM; pH 7.5), NaCl (150 mM) and 
EDTA. (1.0 mM). The column was then eluted with HEPES (5 mM; pH 7.5).  The calcein 
release assay was performed by combining 2 mL of HEPES (20 mM; pH 7.5), NaCl (150 mM) 
and EDTA (1.0 mM) with 20 µl of calcein vesicles. MH5N and MH5C (100 µM) were 
incubated with these vesicles and the fluorescence intensities of released calcein measured 
using a FP-6500 spectrofluorometer (JASCO, Tokyo Japan), with an excitation wavelength of 
490 nm and an emission wavelength of 520 nm.  Membrane lysis of 100% was taken as the 
fluorescence induced by Triton × 100 (20 µl) when used to dissolve the vesicles. The 
percentage lysis achieved by MH5N and MH5C was then calculated relative to this standard. 
 
1.3 Results and discussion 
There is an urgent need for new drugs with novel mechanisms of action to treat cancers 
[1] and here we have investigated the anticancer ability of the amphibian peptide, maximin H5 
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[23,24]. The native peptide, MH5N, was assayed for activity against the glioblastoma cell line, 
T98G and it was found that the peptide had a strong ability to reduce the viability of these 
cancer cells (70%, Figure 1). Regression analysis yielded an IC50 value of 125 μM for MH5N 
(Figure 1), which is comparable to that of other anionic HDPs [20] and also to the levels of the 
native peptide required for antibacterial activity [32]. In contrast, at the same concentrations, 
MH5N exhibited only a low ability to reduce the viability of the non-cancerous, human glial 
cell-line, SVGp12 (circa 10%, Figure 1). In combination, these data show that native maximin 
H5 exhibits specificity for cancer cells and is able to strongly retard the growth of these cells 
in relation to non-transformed cells, which is consistent with the general lack of activity shown 
by the peptide against healthy eukaryotic cells, such as erythrocytes [24,32].  
To investigate the anticancer effects of native maximin H5, CD spectroscopy was used 
to investigate the conformational behaviour of MH5N, which showed that the peptide was 
predominantly unstructured in aqueous solution and exhibited no significant levels of α-helical 
structure (< 10%, Table 1). Similar results have previously been reported for isoforms of 
maximin H5  [32,33], and it is well established that most α-helix forming HDPs require an 
amphiphilic interface, such as that of membranes, to drive the adoption of this secondary 
structure [10,34]. Consistent with these observations MH5N exhibited high levels of α-helical 
structure (68%, Table 1) in the presence of TFE, which is a well known membrane micking 
agent [35] and in the presence of each of the lipid vesicle systems studied (≥ 45%, Table 1, 
Figure 2A).  In particular, the peptide adopted 57.3% α-helicity in the presence of vesicles 
formed from DMPC:DMPS (molar ratio 10:1) (Table 1, Figure 2A), which is a lipid 
composition frequently used to mimic cancer cell membranes [21,36]. It is a distinguishing 
feature of cancer cell membranes that PS forms circa 10% of the total lipid in their outer 
leaflets, as opposed to the membranes of healthy eukaryotic cells where the lipid is primarily 
localised to the inner leaflet [7,10]. In combination, these data suggest that the ability of native 
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maximin H5 to reduce the viability of cancer cells involves the adoption of α-helical structure. 
The levels of this secondary structure are comparable to those mediating the antibacterial 
activity of native maximin H5 [32] and it is well established that the majority of HDPs adopt 
α-helical structure to facilitate their anticancer and antimicrobial activities [7].  
The ability of most HDPs to kill cancer cells is mediated by interactions with the plasma 
membrane of these cells, which, in some cases, can involve non-membranolytic mechanisms 
and intracellular sites of action [7,8]. For example, Cn-AMP2 from Cocos nucifera kills human 
glioblastoma cells via membrane translocation and attack on internal cellular components that 
lead to the induction of anti-proliferative mechanisms [21]. However, in most cases, the 
interaction of HDPs with the plasma membrane of cancer cells leads directly to 
permeabilization of this membrane and cell death via necrosis, and / or disruption of the 
mitochondrial membrane, resulting in cell death through apoptosis [8,37,38]. To investigate 
the ability of native maximin H5 to interact with the plasma membrane of cancer cells, MH5N 
was assayed for the ability to partition into monolayers formed from either DMPC or DMPS, 
and to release dye from vesicles also formed from these lipids. In the case of DMPC, MH5N 
showed high levels of monolayer penetration (Π = 8.6 mN m-1, Table 1, Figure 3A), and vesicle 
lysis (55%, Table 1), indicating a strong hydrophobic contribution to the membrane 
interactions of the peptide. MH5N also showed high levels of interaction with similar lipid 
systems formed from DMPS, strongly penetrating monolayers (Π = 11.3 mN m-1, Table 1, 
Figure 3A) and lysing vesicles (73.1%, Table 1), indicating a strong electrostatic contribution 
to the membrane interactions of the peptide. In combination, these data suggest that the α-
helical structure adopted by the peptide in the presence of membranes is strongly amphiphilic. 
The adoption of high levels of amphiphilic structure is consistent with membranolytic ability 
and known to be a major driver in the anticancer and antimicrobial activity of many HDPs 
[7,39]. The possession of this α-helical structure by native maximin H5 would allow its polar 
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regions to target and interact with the lipid head group region of the membrane whilst its apolar 
regions would be able to concomitantly partition into the hydrophobic bilayer core. Consistent 
with these observations, MH5N induced maximal surface pressure changes of Π = 10.5 mN m-
1 in monolayer mimics of cancer cell membranes (Figure 3C), which is indicative of disruption 
of the acyl chain region [40]. The use of a dye release assay showed that the peptide induced 
high levels of lysis in vesicle mimics of cancer cell membranes (65.6%, Table 1). In 
combination, these results clearly suggest that native maximin H5 possesses high levels of 
membranolytic activity, which facilitate the ability of the peptide to reduce the viability of 
T98G cells. These data would appear to discount the possibility that PE, which is present in the 
outer membrane leaflet of cancer cells [41,42], is able to inactivate the peptide via binding 
mechanisms similar to those described in the case of Escherichia coli (Figure 2) [43,44]. It has 
previously been demonstrated that native maximin H5 has a high affinity for PE and exhibits 
no propensity to partition into the plasma membrane of E. coli but remains anchored to their  
surface, primarily via a variety of peptide-lipid interactions and intra-peptide associations with 
PE head groups [43,44]. It seems likely that these effects are related to the levels of PE in 
membranes given that the molecule forms circa 80% of lipid in the E. coli inner membrane 
[45] but less than 30% of plasma membrane lipid in the glioblastoma cells used here [36].  
The monolayer and lysis data presented here (Table 1, Figure 3A, Figure 3B) also show 
that MH5N interacts more strongly with DMPS model membranes than those formed from 
DMPC, which correlates with the levels of α-helical structure adopted by the peptide in the 
presence of these lipids. CD analysis showed that the levels of α-helicity adopted by MH5N 
was 45% in the presence of vesicles formed from DMPC and rose to 60.75% in the case of 
those formed from DMPS (Table 1, Figure 2A). These results clearly suggest that the peptide 
has a preference for anionic lipid in its membrane interactions, which was confirmed using 
mixed DMPC / DMPS monolayers (lipid ratios varying from 100:1 to 10:1). These studies 
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showed that the maximal surface pressure changes induced in these monolayers by the peptide 
correlated strongly with levels of DMPS (R2 > 0.98, Figure 3C).  In combination, these data 
suggest that anionic lipid promotes the membranolytic ability of native maximin H5 and similar 
results have been reported has been reported for the amphibian peptide, aurein 1.2, which has 
been shown to lyse membranes of the T98G cancer cells studied here [36]. A requirement for 
anionic lipid would also seem to help explain the fact that native maximin H5 low efficacy 
against non-cancerous SVGp12 cells (Figure 1) whose membranes are electrically neutral 
overall [36]. 
The preference shown by MH5 for anionic lipid data would also seem to support the 
view that, although anionic, the native peptide effectively functions as a cationic AMP.  Studies 
on the antibacterial action of native maximin H5 suggested that the ability of the peptide to 
target and interact with bacterial membranes was mediated by the amidated residues at its two 
termini [32,33]. To investigate this possibility for the anticancer action of the peptide, the above 
work was repeated using a deaminated isoform of maximin H5, MH5C, which exhibited lower 
levels of α-helical structure in the presence of cancer membrane mimics (44.8%, Table 1, 
Figure 2B) as well as decreased levels of interaction with DMPC (Π = 7.8  mN m-1, Table 1, 
Figure 3B) and DMPS monolayers (Π =  10.2 mN m-1, Table 1, Figure 3B). In combination, 
these data suggest that the C-terminal amide of native maximin H5 helps maintain the levels 
of amphiphilicity possessed by this architecture that are required for the optimal lysis of  cancer 
cell membranes. Indeed, it is well established that the propensity of AMPs to form α-helical 
structure is strongly favoured by the presence of C-terminal amide groups, which provide an 
additional hydrogen bond for α-helix stabilisation [46,47]. Consistent with a loss of membrane 
interactive α-helical structure, MH5C showed a reduced ability to penetrate monolayer mimics 
of cancer cell membranes (Π = 8.1 mN m-1, Table 1, Figure 3B) and induce the lysis of vesicle 
mimics of these membranes (56.6%, Table 1). Clearly, these data also suggest that loss of the 
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C-terminal amide possessed by MH5N reduces the ability of the peptide to promote its lysis of 
cancer cell membranes through targeting and interaction with anionic lipid components of these 
membranes. Confirming his suggestion, it was found that the maximal surface pressure changes 
induced in mixed DMPC/ DMPS monolayers by MH5C were circa 2.5 mN m-1 lower than 
those induced by MH5N at corresponding lipid compositions but still correlated strongly with 
levels of DMPS (R2 > 0.98, Figure 3C). In combination, these data clearly suggest that the C-
terminal amide possessed by native maximin H5 plays a key role in optimizing the ability of 
the peptide to kill cancer cells and facilitates this ability through multiple functions. Indeed, 
the combined effects of C-terminal deamination on the membrane interactive potential of 
MH5N could help explain the kinetics of insertion into monolayers of DMPC and DMPS 
observed for MH5C (Figure 3). As can be seen from Figure 3A, insertion into these monolayers 
to achieve maximal surface pressure changes took MH5N less than a second whereas Figure 
3B shows that MH5C took of the order of 450 seconds. These data clearly suggest the C-
terminal amide of native maximin H5 is able to enhance not only enhance the depth of insertion 
shown by the peptide into cancer cell membranes but also its rate of insertion into these 
membranes. 
 
1.4 Conclusion 
In summary, here we have reported what appears to the first major example of anionic 
amphibian HDPs with anticancer activity, which involves membranolytic mechanisms that are 
promoted by anionic lipid and require both of the peptide’s terminal amide groups for optimal 
action. The peptide showed specificity for cancer cells over non-cancerous cells and in 
combination, these results reinforce the view that the anticancer action of HDPs is dependent 
on the properties of both these peptides and the membranes of target cells [7]. The data 
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presented here also shows that the anticancer activity of native maximin H5 exhibits a number 
of structure / function relationships that are shared by the antibacterial action of the peptide 
[32].  This observation supports the view that the ability of HDPs to kill cancer and microbial 
cells is generally promoted by common mechanisms and in particular that these peptides target 
these cells via the negative surface charge carried by their membranes [48,49].  A number of 
mechanisms to describe the antibacterial and anticancer action of HDPs have been proposed, 
including the carpet, the toroidal pore, the barrel stave pore and the tilted peptide models, and 
clearly, based on the data presented here, no particular model could be definitively assigned to 
the anticancer action of maximin H5 [7,10,39,50–52]. However, it is interesting to note that 
the peptide appears to form tilted α-helical structure, which is required to promote its 
membrane interactions [32,44], and previous studies have shown that C-terminal deamidation 
can reduce the anticancer efficacy of tilted HDPs [53]. Moreover, the possession of this 
structural motif could indicate the potential to use a recently described, novel mechanism of 
membrane disruption in which tilted HDPs target the outer leaflet of the bilayer. According to 
this mechanism, the insertion of tilted peptides into the membrane triggers a rapid and 
continuous thinning of the outer leaflet; this action is accompanied by the formation of pores 
in the leaflet, which coalesce and cause local membrane rupture, leading to cell death [54]. As 
a final comment, it has recently been opined that anionic HDPs have the potential for a number 
of medical and biotechnological applications but appear to receive relatively little research 
attention in the literature [17,18,55]. Given the data presented here, it would seem that these 
peptides may represent an untapped potential source of novel anticancer agents that is awaiting 
full exploitation and merits much greater investigation. 
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Table 1. Biophysical properties of membranolytic maximin H5 isoforms  
 Maximin H5 Deaminated maximin H5 
 α-
helicity (%) 
Π (mN 
m-1) 
Lysis (%) α-
helicity (%) 
Π (mN 
m-1) 
Lysis (%) 
PBS buffer 9 - - 6 - - 
TFE 68 - - 62 - - 
DMPC 45.0 8.6 55.3 35.3 7.8 46.2 
DMPS/DMPC 
(10:1) 
57.3 10.5 65.7 44.8 8.1 56.6 
DMPS 60.75 11.3 73.1 50.6 10.2 63.5 
 
Π indicates the maximal surface pressure changes in lipid monolayers by isoforms of maximin 
H5. 
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Figure 1. The activity of maximin H5 against cancer cell lines 
 
 
 
 
 
Figure 1 shows the effect of MH5N on the viability of cells of T98G, which is a glioblastoma 
cell line (red). Increasing concentrations of the peptide led to progressively larger reductions 
in the viability the cell lines until at a concentration 150 µM, these reductions were circa 70% 
as compared to controls. In contrast, at the same peptide concentration, MH5N induced 
reductions in the viability of the non-cancerous, human glial cell-line, SVGp12 (blue), of circa 
10% as compared to controls. In all cases, experiments were performed in quadruplicate and 
the error bars represent the standard deviation. Non-linear regression analysis was used to yield 
the concentration of peptides that inhibited 50% of cancer cell growth (IC50) when compared 
to untreated controls.   
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Figure 2. CD structural analysis of maximin H5 isoforms in lipid systems 
 
 
 
Figure 2 shows CD spectra for MH5N (Figure 2A) and MH5C (Figure 2B) in the presence of 
vesicles formed from DMPS (Dotted grey), DMPC (Solid grey) and DMPC / DMPS (molar 
ratio 10:1) (Solid black). In all cases, these spectra showed negative bands around 222 and 210 
nm, indicative of the presence of α-helical structure. Analysis of these spectra showed that α-
helical contributions to the structure of MH5N ranged between 46.0% and 64.5% with the 
levels of this α-helicity rising as the DMPS content of membranes increased (Table 1). 
Corresponding analysis of MH5C (Figure 2B) showed that α-helical contributions to the 
structure of this peptide ranged between 35.7% and 51.4 % and showed a similar correlation 
with DMPS membrane content (Table 1). For both peptides, the remaining structural 
contributions to their molecular architecture came from random coil and β-type structures 
(Figures 2A and 2B).  A lipid composition of DMPC / DMPS (molar ratio 10:1) was taken to 
represent cancer cell membranes as previously described [21,36] and in the presence of these 
membranes, MH5N and MH5C exhibited 57.5% and 45.9% α-helicity respectively (Table 1).  
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Figure 3. The interaction of maximin H5 isoforms with lipid monolayers 
 
 
 
Figure 3A shows the interaction of MH5N with monolayers formed from DMPS (black) and 
DMPC (grey), which induced maximal surface pressure changes of Π = 11.3 and 8.6 mN m-1 
respectively. Figure 3B shows the corresponding interactions of MH5C with monolayers 
formed from DMPS (black) and DMPC (grey), which induced maximal surface pressure 
changes of Π = 10.2 mN m-1 and 7.8 mN m-1 respectively (Table 1). Figure 3C show that the 
maximal surface pressure changes induced in membranes by both peptides correlated strongly 
with levels of DMPS in these membranes (R2 > 0.98). Lipid compositions of DMPC / DMPS 
(molar ratio 10:1) were taken to represent cancer cell membranes as previously described 
[21,36] and for these monolayers, MH5N and MH5C induced maximal surface pressure 
changes of Π = 10.5 mN m-1 and 8.1 mN m-1 respectively (Table 1). Surface pressure changes 
were determined relative to a surface pressure of 30 mN m−1, which is generally taken as that 
of naturally occurring biological membranes [31]. These experiments were performed in 
quadruplicate and the error bars represent the standard deviation. 
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